STOCK TITAN

ZIMVIE INC Stock Price, News & Analysis

ZIMV Nasdaq

Welcome to our dedicated page for ZIMVIE news (Ticker: ZIMV), a resource for investors and traders seeking the latest updates and insights on ZIMVIE stock.

ZimVie Inc (ZIMV) delivers innovative dental and spine solutions through advanced biomaterials and digital workflow integration. This news hub provides investors and medical professionals with centralized access to official updates spanning product developments, financial disclosures, and strategic initiatives.

Track announcements across ZimVie's core segments: dental innovations like implant surface technologies and CAD/CAM restorative systems, plus spine surgery advancements in fusion devices and surgical instrumentation. Receive timely updates on regulatory milestones, partnership agreements, and clinical research outcomes.

Our curated news collection enables efficient monitoring of ZimVie's progress in merging digital planning tools with medical device engineering. Discover updates on RealGUIDE® software enhancements, biomaterial research breakthroughs, and market expansion strategies while maintaining compliance with financial disclosure standards.

Bookmark this page for structured access to ZimVie's evolving position in life sciences. Combine technical insights with corporate updates to inform your analysis of this dual-segment medical technology innovator.

Rhea-AI Summary

ZimVie has launched the TSX Implant, a significant innovation in its dental solutions portfolio. Designed for immediate extraction and loading, the TSX Implant aims to enhance peri-implant health and improve placement predictability in various bone types. This implant integrates over 20 years of clinical data, emphasizing features that promote long-term osseointegration and stability. The implant was recently introduced at the American Academy of Periodontology’s annual meeting, showcasing ZimVie’s commitment to advancing digital dental workflows and improving patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
none
-
Rhea-AI Summary

ZimVie Inc. (Nasdaq: ZIMV) will announce its third quarter 2022 financial results on November 9, 2022, after market close. Following the results, the management will conduct a conference call at 4:30 p.m. Eastern Time. Interested participants can register online and are encouraged to do so at least 15 minutes prior to the call. ZimVie specializes in dental and spine markets, providing a range of products for various spine pathologies and dental procedures. The company became an independent entity in March 2022, focusing on strategic growth in its sectors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
conferences earnings
-
Rhea-AI Summary

ZimVie Inc. (ZIMV) has announced the launch of the Virage Navigation System, a new tool designed for spinal surgery that enhances pedicle screw navigation across the entire spine. This system features a 360° Omnidirectional Extreme-Angle Screw allowing for improved screw placement with reduced operating times. It integrates with existing navigation systems, complementing the prior Vital Navigation System. This innovation reflects ZimVie’s commitment to advancing spinal technologies and enhancing surgical outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
none
Rhea-AI Summary

ZimVie Inc. (Nasdaq: ZIMV), a leader in dental and spine markets, announced its participation in Morgan Stanley's 20th Annual Global Healthcare Conference in New York. Management, including President Vafa Jamali and CFO Rich Heppenstall, will present on September 13, 2022, at 7:20 AM EDT. The event will be accessible via a live and archived webcast. Established in March 2022 as a spin-off from Zimmer Biomet, ZimVie is dedicated to enhancing life sciences with innovative dental and spine solutions, serving over 70 countries worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.96%
Tags
conferences
-
Rhea-AI Summary

ZimVie Inc. (ZIMV) reported Q2 2022 net sales of $233.4 million, down 11.5% from the prior year. The company experienced a net loss of ($8.7 million) with a net loss margin of (3.7%). Adjusted net income was $17.6 million and diluted EPS was (0.33), while adjusted diluted EPS was $0.67. Cash reserves rose to $130.1 million. The company revised its 2022 net sales guidance down to $915 - $930 million from $1.0 billion, citing foreign exchange headwinds. Adjusted EPS guidance was also lowered to $1.80 - $2.00.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.44%
Tags
-
Rhea-AI Summary

ZimVie Inc. (Nasdaq: ZIMV), a leader in dental and spine markets, will report its financial results for Q2 2022 after market close on August 10, 2022. An audio webcast will follow at 4:30 p.m. ET, allowing investors to gain insights into the company’s performance post-spin-off from Zimmer Biomet. ZimVie focuses on a comprehensive product portfolio for spine and dental solutions, serving over 70 countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
conferences earnings
Rhea-AI Summary

ZimVie Inc. announced a positive medical policy from Anthem Blue Cross Blue Shield regarding the use of its Tether™ device for treating pediatric scoliosis. Effective July 6, 2022, this decision expands treatment eligibility to over 30 million members. The Tether™ device is the first FDA-approved non-fusion treatment for scoliosis, backed by more than seven years of clinical data, with over 1,200 children treated since its introduction in 2019. This development is anticipated to enhance access to motion-preserving treatments for children and may encourage other insurers to follow suit.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.07%
Tags
none
-
Rhea-AI Summary

ZimVie Inc. (Nasdaq: ZIMV) announced the launch of the FDA-cleared T3® PRO Tapered Implant and Encode® Emergence Healing Abutment on June 16, 2022. These products enhance dental restoration care with improved aesthetics and functionality. The T3 PRO builds on the existing T3 Implant line, demonstrating advanced design and high primary stability for immediate function. The Encode Emergence Abutment streamlines the impression process and promotes patient comfort. ZimVie aims to roll out these innovations in the U.S. and other regions as regulations permit.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
none
-
Rhea-AI Summary

ZimVie Inc. (Nasdaq: ZIMV) reported Q1 2022 net sales of $234.7 million, reflecting a 4.6% decrease year-over-year. Dental segment sales increased by 6.4% to $120.6 million, while spine sales fell by 13.9% to $114.1 million, attributed to market exits and product discontinuation. The company posted a net loss of $25.7 million or 10.9% of sales, with diluted EPS at ($0.98), but adjusted diluted EPS improved to $0.50. Adjusted EBITDA was $33.8 million, a decline from the previous year. ZimVie reaffirmed its 2022 guidance of $1.0 billion in net sales and adjusted EPS between $2.10 to $2.30.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.87%
Tags
Rhea-AI Summary

ZimVie Inc. (Nasdaq: ZIMV), a leader in the dental and spine markets, will report its first-quarter 2022 financial results on May 5, 2022, after market close. A conference call with management is scheduled for 4:30 p.m. Eastern Time, allowing investors to engage by dialing in. ZimVie became an independent publicly traded entity in March 2022, having spun off from Zimmer Biomet, focusing on innovative dental and spine solutions. The company operates globally, supporting customers in over 70 countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.41%
Tags
conferences earnings

FAQ

What is the current stock price of ZIMVIE (ZIMV)?

The current stock price of ZIMVIE (ZIMV) is $9.36 as of May 2, 2025.

What is the market cap of ZIMVIE (ZIMV)?

The market cap of ZIMVIE (ZIMV) is approximately 262.9M.
ZIMVIE INC

Nasdaq:ZIMV

ZIMV Rankings

ZIMV Stock Data

262.88M
27.07M
2.34%
88.28%
1.45%
Medical Devices
Dental Equipment & Supplies
Link
United States
PALM BEACH GARDEN